Nowadays, protein overexpressions and gene rearrangements of MYC and BCL2 involved in “double-protein” and “double-hit” DLBCL are the most commonly used biomarkers to predict the poor prognosis in DLBCL patients treated with R-CHOP. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.